The CDH6 antibody targets Cadherin-6 (CDH6), a calcium-dependent cell adhesion molecule belonging to the cadherin superfamily. CDH6. also known as K-cadherin, plays critical roles in tissue morphogenesis, cell signaling, and maintaining cellular polarity during embryonic development, particularly in the kidneys, nervous system, and thyroid. Structurally, it contains extracellular cadherin repeats that mediate homophilic binding and intracellular domains that interact with catenins to link the cytoskeleton. Dysregulation of CDH6 has been implicated in cancer progression, including renal cell carcinoma, ovarian cancer, and thyroid malignancies, where its overexpression correlates with metastasis and poor prognosis. CDH6 antibodies are widely used in research to study cell adhesion dynamics, tumor biology, and developmental processes. They enable detection of CDH6 expression via techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence. Recent interest in CDH6 as a therapeutic target has grown, particularly in antibody-drug conjugates (ADCs) for cancers. However, its tissue-specific roles and signaling mechanisms remain under investigation. Commercial CDH6 antibodies are typically validated for specificity against human, mouse, or rat isoforms, supporting both basic research and clinical biomarker studies.